Gilead Sciences, Inc. (GIS.DE)

60,89 -0,19 (-0,31%) Al cierre: 05:35PM CEST

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 18.000

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Daniel P. O'Day	Chairman & CEO	6,56M	N/A	1964
Mr. Andrew D. Dickinson	Chief Financial Officer	2,5M	N/A	1970
Ms. Deborah H. Telman	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary	2,4M	N/A	1965
Ms. Johanna Mercier	Chief Commercial Officer	2,9M	N/A	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2,62M	N/A	1964
Ms. Sandra Patterson	Senior VP, Corporate Controller & Principal Accounting Officer	N/A	N/A	1967
Ms. Jacquie Ross C.F.A.	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources	N/A	N/A	1976
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio	N/A	N/A	1962
Dr. Rudolf Ertl	Senior Vice President of Commercial Operations of Australia, Canada, Europe	N/A	N/A	1946

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gobierno corporativo

El ISS Governance QualityScore de Gilead Sciences, Inc., a día 1 de mayo de 2024, es 2. Las puntuaciones base son Auditoría: 3; Tablero: 5; Derechos de los accionistas: 1; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.